ARCH Venture Partners
Founded: 1992
Number of deals: 20
Number of companies: 15
Scoop: ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. The firm invests primarily in companies co-founded with scientists and entrepreneurs.
In its life science division, ARCH invests mainly in biopharmaceuticals, bioinformatics, gene therapy, medical devices, and other breakthrough technology. The firm looks mainly for early-stage investment opportunities and focuses on platform technologies. Notable portfolio companies include Alnylam, BIND Biosciences, Elixir Pharmaceuticals, Ensemble Discovery Corp., Fate Therapeutics, Illumina, Trubion Pharmaceuticals, VLST and XenoPort.
Portfolio Company News:
UM spinoff lands $36M venture deal
Agios Pharmaceuticals - 2009 Fierce 15
Achaogen - 2009 Fierce 15
Accelerator Launches XORI With Series A
Lycera Closes $36 Million Series A Financing
U.S., Norwegian, Irish biotechs raise millions
SHARE
WITH: